Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
Conditions
Interventions
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)
Mycophenolic Acid 0.1%
+5 more
Locations
40
United States
Cornea and Cataract Consultants of Arizona PC
Phoenix, Arizona, United States
Canyon City EyeCare
Azusa, California, United States
Inland Eye Specialists
Hemet, California, United States
North Valley Eye Medical Group Inc.
Mission Hills, California, United States
LoBue Laser and Eye Medical Center
Murrieta, California, United States
Eye Research Foundation
Newport Beach, California, United States
Start Date
January 11, 2021
Primary Completion Date
March 25, 2022
Completion Date
March 25, 2022
Last Updated
May 11, 2025
NCT07463950
NCT07363824
NCT07396441
NCT05865379
NCT05865457
NCT06984549
Lead Sponsor
Surface Ophthalmics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions